Thursday, February 7, 2019 – Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, announces its partnership with a new Centre for Doctoral Training (CDT) at the University of Oxford, supported by EPSRC (The Engineering and Physical Sciences Research Council).

The goal of the centre is to provide the next generation of doctoral level students with full support, to be able to combat research and innovation challenges across the engineering and physical sciences landscape. The Centre will be located within the Big Data Institute, and will play a leading role in training of health data scientists. The students will be able to complete their doctoral research under the guidance of an academic supervisor and work with a wide range of partner organisations, including Insilico Medicine.

“Insilico Medicine is one of the first AI companies to combine the expertise in artificial intelligence applied to the cutting-edge medicinal chemistry and target identification. Our set of software tools and AI libraries, deep domain expertise in target identification and medicinal chemistry, and focus on aging and age-related diseases will contribute to the educational process of the Centre for Doctoral Training. It is a wonderful initiative that makes the UK more attractive for companies like ours”, – said Alex Zhavoronkov, Ph.D., founder, and CEO of Insilico Medicine, Inc.

Read more…